OUR LADY OF FATIMA NAME: SECTION: GROUP #

UNIVERSITY COURSE: DATE:

SCHEDULE:
College of Nursing

DRUG STUDY Diagnosis: Lung Cancer Patient’s Initials: P

NURSING
MEDICATIO ACTION DRUG TO DRUG
INDICATION CONTRAINDICATION INTERACTION ADVERSE EFFECTS CONSIDERATI
N ON

Generic Name
Pharmacodynamics  Initial and  Contraindicated in Drug-drug.  CNS: dizziness,  Stress importance of
secondary patients - Aspirin: Increases risk of confusion, adequate fluid intake
Carboplatin
Antitumor action: (palliative) hypersensitive to bleeding. Avoid use together. peripheral and increase in urine
Carboplatin causes treatment of cisplatin, platinum- - Bone marrow suppressants neuropathy, central output to facilitate
Brand Name
interstrand cross-linking of ovarian containing (including radiation therapy): neurotoxicity, uric acid excretion.
Paraplatin
DNA strands, thereby carcinoma, compounds, or Increases hematologic paresthesia,  Tell patient to report
inhibiting DNA replication, retinoblastoma, mannitol and in toxicity. Monitor patient tinnitus
Classification asthenia, pain, CVA
transcription, and all division advanced patients with severe closely. immediately, to
 alkylating
- Myelosuppressives: Causes  CV: cardiac failure,
of cancerous cells. bladder cancer , bone marrow prevent permanent
agent (not embolism.
Pharmacokinetics lung cancer , suppression or additive myelosuppression. hearing loss. Patient
specific to  EENT: visual
head and neck bleeding. Monitor patient. should have
phase of cell disturbances,
cycle) Absorption: Administered cancer , Wilms’ - Nephrotoxic drugs: audiometric testing
tumor , primary Causes additive ototoxicity, altered before initial and
 antineoplastic I.V.
Distribution: Volume of brain tumor , nephrotoxicity of taste. subsequent course of
testicular carboplatin. Use  GI: constipation, drug therapy.
Dosage & Frequency distribution is about equal
- to total body water. Drug neoplasm , cautiously. diarrhea, nausea,  Advise patient to
isn’t protein-bound but cervical cancer . vomiting. avoid exposure to
degraded to platinum-  Hematologic: THRO people with
Stock Dose containing products, which MBOCYTOPENIA, le infections.
are 87% protein-bound at 24 ukopenia,  NEUTRO  Instruct patient
Injection: 50-mg, 150- hours. PENIA, anemia, BO to promptly
mg, 450-mg vials Metabolism: Hydrolyzed to NE MARROW report unusual
form hydroxylated and SUPPRESSION. bleeding or
aquated species. Half-life of  Skin: alopecia. bruising.
drug is 2 to 3 hours;  Other: hypersensiti
terminal half-life for vity reactions,
platinum is 4 to 6 days. anaphylaxis..
Excretion: 65% is excreted
by the kidneys within 12
hours, 71% within 24 hours.
Enterohepatic recirculation
may occur.
MCALIM2020
 Generic Name
Pharmacodynamics  Ovarian Cancer  Patients with solid Serious interactions of paclitaxel  Neutropenia (78-  The drug
paclitaxel  Breast Cancer tumors or patients include: 100%) should be
Laxative and bowel  Non-small Cell with AIDS-related  Alopecia (55-96%) administered
evacuant action: Acts as an Lung Cancer Kaposi’s sarcoma  adenovirus types 4 and 7  Anemia (47-96%) under the
Brand Name
osmotic product. With  AIDS-related with baseline live, oral  Arthralgia/myalgia supervision of
Taxol
sodium sulfate as the major Kaposi's neutrophil counts of  eluxadoline (93%) an experienced
sodium source, active <1,500 cells/mm3 cancer
Classification Sarcoma (2nd-  idarubicin  Diarrhea (90%)
sodium absorption is line Treatment) chemotherapy
Antineoplastics,  idelalisib  Leukopenia (90%)
markedly reduced. Diarrhea  Documented physician in a
Antimicrotubular  Pancreatic  influenza virus  Nausea/vomiting (9-
results, which rapidly cleans hypersensitivity to facility
(Taxanes) Cancer (Off- vaccine trivalent, 88%)
the bowel, usually within 4 drug or excipients. equipped to
label) adjuvanted  Opportunistic
hours. diagnose and
Dosage & Frequency  ivacaftor infections (76%)
- manage
 nefazodone  Peripheral
complications
Pharmacokinetics  palifermin neuropathy (42-79%)
Stock Dose  quinidine  Thrombocytopenia  The drug is
injectable solution (4-68%) contraindicated
Protein bound: 89-98%
6mg/mL in patients with
Vd: 227-688 L/m²  Paclitaxel has moderate  Mucositis (5-45%)
solid tumor
Metabolism: Metabolized interactions with at least  Hypersensitivity (2-
who have
by CYP2C8, CYP3A4 98 different drugs. 45%)
baseline
Metabolites: 6-alpha-  Paclitaxel has mild  Renal impairment
neutrophil
hydroxypaclitaxel (major) interactions with at least (34%) counts <1500
Half-life elimination: 27hr 81 different drugs.  Hypotension (17%) cells/m³ and in
terminal  1-10% patients with
Excretion: Feces (20%);  Bradycardia (3%) AIDS-related
urine (4%)  <1% Kaposi sarcoma
 Grand mal seizures who have
 Cardiac conduction baseline
abnormalities neutrophil
counts <1000
cells/m³;
perform
frequent
peripheral
blood counts to
monitor for
occurrence of
bone marrow
suppression,
primarily
neutropenia,
which may
result in
infection
 Fatal MCALIM2020
 anaphylaxis and
severe
hypersensitivity
reactions
characterized
by dyspnea and
hypotension
requiring
treatment,
angioedema,
and generalized
urticaria have
occurred in
patients despite
premedication
 Pretreat all
patients with
corticosteroids,
diphenhydrami
ne, and H2
antagonists
 Do not
rechallenge
patients who
experience
severe
hypersensitivity
reactions to the
drug
Generic Name
Pharmacodynamics  Small-cell  Contraindicated in Drug-drug.  CNS: peripheral neuropathy.  Advise patient
carcinoma of patients CV: hypotension (from too- about
Antineoplastic action: Cisplatin:  Increases
Etoposide-VP16 the lung. hypersensitive to rapid infusion). potential
Etoposide exerts cytotoxic cytotoxicity of cisplatin
 Testicular etoposide, GI: nausea and vomiting, adverse
action by arresting cells in carcinoma teniposide, or against certain tumors. May
Brand Name anorexia, reactions, and
the metaphase portion of cell Cremaphor EL. Use be used for this purpose.
 AIDS-related diarrhea,  abdominal instruct
division. Drug also inhibits Kaposi’s cautiously in patients Warfarin:  May cause
Toposar, VePesid pain, stomatitis. patient to
cells from entering mitosis sarcoma who have had elongation of PT and
Hematologic: anemia,  myel immediately
and depresses DNA and cytotoxic or INR. Monitor patient
osuppression,  LEUKOPENIA report
RNA synthesis at the G2 radiation therapy. closely.
Classification , THROMBOCYTOPENIA.  vomiting that
portion of the cell cycle.
Skin: reversible alopecia. occurs shortly
podophyllotoxin Other: anaphylaxis.
(specific to G2 and late Pharmacokinetics
after a dose.
S phases of cell cycle  Advise patient
Absorption: Only to report sore
moderately absorbed across MCALIM2020
antineoplastic the GI tract after oral throat, fever,
administration. Etoposide’s or unusual
Dosage & Frequency bioavailability ranges from bruising or
40 mg/day 25% to 75%, with an bleeding.
average of 50% of the dose
 Advise patient
being absorbed.
to avoid
Distribution: Distributed
Stock Dose exposure to
widely into body tissues; the
Capsules: 50 mg people with
highest levels are found in
Injection: 20-mg/ml infections.
the liver, spleen, kidneys,
multiple-dose vials  Tell patient
healthy brain tissue, and
brain tumor tissue. It crosses not to receive
the blood-brain barrier to a immunizations
limited and variable extent. during therapy
Etoposide is about 94% with
bound to serum albumin. etoposide. Tell
Metabolism: Only a small other family
portion of a dose of members to
etoposide is metabolized. avoid
Metabolism occurs in the immunizations
liver. during this
Excretion: Excreted time as well.
primarily in the urine as  Advise patient
unchanged drug. A smaller to use
portion of a dose is excreted contraceptive
in the feces. The plasma measures
elimination of etoposide is during therapy
described as biphasic, with
an initial phase half-life of
about 1/2 to 2 hours and a
terminal phase of about 5
1/4 to 11 hours.

MCALIM2020